Archemix Outlicenses Aptamers To Ophthotech
This article was originally published in The Pink Sheet Daily
Executive Summary
Ophthotech, a new firm formed by several ex-Eyetech managers, will develop anti-C5 compounds as candidates to treat age-related macular degeneration.
You may also be interested in...
Archemix Reduces Aperture to Pursue Orphan Diseases
Archemix has consolidated IP in the aptamer space and enjoyed success in partnering its technology. But public markets have frozen the company out and it is now focusing on orphan hematologic diseases. The move should help the company conserve cash while creating earlier out-licensing opportunities as Archemix transitions into later-stage development.
Ophthotech Will Take Biogen/PDL Drug Volociximab Into The Clinic For AMD
Alpha 5 beta 1 integrin antagonist will move into the clinic “shortly,” CEO Patel tells “The Pink Sheet” DAILY.
Ophthotech Will Take Biogen/PDL Drug Volociximab Into The Clinic For AMD
Alpha 5 beta 1 integrin antagonist will move into the clinic “shortly,” CEO Patel tells “The Pink Sheet” DAILY.